

Title (en)

METHODS FOR TREATING CANCER AND FOR MEDIATING CHEMOTAXIS OF DENDRITIC CELLS

Title (de)

VERFAHREN ZUR BEHANDLUNG VON KREBS UND VERMITTLUNG VON DENDRITISCHEN ZELLEN-CHEMOTAXIS

Title (fr)

METHODES DE TRAITEMENT DU CANCER ET DE MEDIATION DE LA CHIMIOTAXIE DES CELLULES DENDRITIQUES

Publication

**EP 1140141 A2 20011010 (EN)**

Application

**EP 99968968 A 19991228**

Priority

- US 9931096 W 19991228
- US 11449898 P 19981231

Abstract (en)

[origin: WO0038706A2] The invention is based on the novel observation, reported herein, that SLC inhibits the growth of tumors in vivo and is a potent chemokine for Dendritic Cells (DC). Thus, the invention provides a method of treating cancer or hyperproliferative disorder in a mammalian subject, comprising: administering a therapeutically effective amount of an SLC to said subject. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids. The methods of the invention are useful in the treatment of cancer and hyperproliferative disorders. In addition, the invention provides methods for modulating dendritic cell function in a mammal, said method comprising administering a therapeutically effective amount of an SLC agent to said mammal, said agent selected from the group consisting of: SLC polypeptides, SLC polypeptide variants, SLC polypeptide fragments, polynucleotides encoding SLC polypeptides, variants and fragments, anti-SLC antibodies and ligands for the CCR7 receptor. Such methods can be used to increase or decrease an immune response, particularly a primary immune response, in a mammal. The methods are particularly useful in the prevention of graft rejection and in the treatment of autoimmune disease. Alternatively, the methods may be used to enhance an immune response.

IPC 1-7

**A61K 38/19**; **A61K 48/00**; **A61P 35/00**

IPC 8 full level

**C12N 15/02** (2006.01); **A61K 31/711** (2006.01); **A61K 38/00** (2006.01); **A61K 38/19** (2006.01); **A61K 38/20** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/00** (2006.01); **A61P 43/00** (2006.01); **C07K 14/47** (2006.01)

CPC (source: EP)

**A61K 38/195** (2013.01); **A61K 38/2013** (2013.01); **A61P 35/00** (2017.12); **A61P 37/00** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

See references of WO 0038706A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

**WO 0038706 A2 20000706**; **WO 0038706 A3 20001123**; **WO 0038706 A9 20020822**; AU 2715700 A 20000731; EP 1140141 A2 20011010; JP 2002533402 A 20021008

DOCDB simple family (application)

**US 9931096 W 19991228**; AU 2715700 A 19991228; EP 99968968 A 19991228; JP 2000590657 A 19991228